Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Phase 2 study of sodium phenylbutyrate in ALS.

Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums..

Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.

PMID:
18688762
2.

Histone deacetylation and motor neuron degeneration.

Schmalbach S, Petri S.

CNS Neurol Disord Drug Targets. 2010 Jul;9(3):279-84. Review.

PMID:
20406183
3.

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.

Gore SD, Carducci MA.

Expert Opin Investig Drugs. 2000 Dec;9(12):2923-34. Review.

PMID:
11093362
4.

Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases.

Garbes L, Riessland M, Wirth B.

Curr Pharm Des. 2013;19(28):5093-104. Review.

PMID:
23448465
5.

Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS).

Lee J, Ryu H, Keum G, Yoon YJ, Kowall NW, Ryu H.

Curr Med Chem. 2014;21(31):3576-82. Review.

PMID:
25005187
6.

Clinical and experimental applications of sodium phenylbutyrate.

Iannitti T, Palmieri B.

Drugs R D. 2011 Sep 1;11(3):227-49. doi: 10.2165/11591280-000000000-00000. Review.

7.

Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases.

Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL.

Curr Med Chem. 2008;15(13):1263-73. Review.

PMID:
18537606
8.
9.

Histone deacetylases and their role in motor neuron degeneration.

Lazo-Gómez R, Ramírez-Jarquín UN, Tovar-Y-Romo LB, Tapia R.

Front Cell Neurosci. 2013 Dec 5;7:243. doi: 10.3389/fncel.2013.00243. Review.

10.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005225. doi: 10.1002/14651858.CD005225.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD005225.

PMID:
20556761
11.

Histone deacetylase inhibitors in cancer therapy.

Rasheed WK, Johnstone RW, Prince HM.

Expert Opin Investig Drugs. 2007 May;16(5):659-78. Review.

PMID:
17461739
12.

Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.

Gabrielli BG, Johnstone RW, Saunders NA.

Curr Cancer Drug Targets. 2002 Dec;2(4):337-53. Review.

PMID:
12470210
13.

Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers.

Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE.

Adv Exp Med Biol. 1997;400A:501-5. Review.

PMID:
9547596
14.
Items per page

Supplemental Content

Support Center